A5063385671- Pain Management and Treatment
- Transcranial Magnetic Stimulation Studies
- Neurological disorders and treatments
- Musculoskeletal pain and rehabilitation
- Botulinum Toxin and Related Neurological Disorders
- Parkinson's Disease Mechanisms and Treatments
- Migraine and Headache Studies
- Trigeminal Neuralgia and Treatments
- Pain Mechanisms and Treatments
- Sympathectomy and Hyperhidrosis Treatments
- Virus-based gene therapy research
- Spine and Intervertebral Disc Pathology
- Genetic Neurodegenerative Diseases
- Obsessive-Compulsive Spectrum Disorders
- Neuroscience and Neural Engineering
- Intracranial Aneurysms: Treatment and Complications
- Myofascial pain diagnosis and treatment
- Head and Neck Surgical Oncology
- Anesthesia and Pain Management
- Laser Applications in Dentistry and Medicine
- Lysosomal Storage Disorders Research
- Peripheral Nerve Disorders
- Pain Management and Placebo Effect
- Meningioma and schwannoma management
- Vascular Malformations Diagnosis and Treatment
Inserm
2005-2024
Centre Hospitalier Universitaire de Nantes
2008-2024
Nantes Université
2005-2024
Hôpital Nord
2009-2024
Hôpital Laennec
2004-2024
Université de Montpellier
2024
Hôpital Gui de Chauliac
2024
Institut de Génomique Fonctionnelle
2024
Centre National de la Recherche Scientifique
2024
Centre d'Investigation Clinique de Nantes
2008-2022
Subthalamic stimulation reduces motor disability and improves quality of life in patients with advanced Parkinson's disease who have severe levodopa-induced complications. We hypothesized that neurostimulation would be beneficial at an earlier stage disease.In this 2-year trial, we randomly assigned 251 early complications (mean age, 52 years; mean duration disease, 7.5 years) to undergo plus medical therapy or alone. The primary end point was life, as assessed the use Disease Questionnaire...
Severe, refractory obsessive-compulsive disorder (OCD) is a disabling condition. Stimulation of the subthalamic nucleus, procedure that already validated for treatment movement disorders, has been proposed as therapeutic option.In this 10-month, crossover, double-blind, multicenter study assessing efficacy and safety stimulation we randomly assigned eight patients with highly OCD to undergo active nucleus followed by sham stimulation. The primary outcome measure was severity OCD, assessed...
Recent trials in patients with neurodegenerative diseases documented the safety of gene therapy based on adeno-associated virus (AAV) vectors deposited into brain. Inborn errors metabolism are most frequent causes neurodegeneration pre-adulthood. In Sanfilippo syndrome, a lysosomal storage disease which heparan sulfate oligosaccharides accumulate, onset clinical manifestation is before 5 years. Studies mouse model showed that providing missing enzyme α-N-acetyl-glucosaminidase to brain cells...
Greater occipital nerve stimulation (ONS) has been recently proposed to treat severe chronic cluster headache patients (CCH) refractory medical treatment. We report the results of a French multidisciplinary cohort study.Thirteen CCH were operated and data collected prospectively. All them suffered from according International Headache Society classification, lasting for more than 2 years, pharmacological prophylactic treatment with adequate trials, at least one daily attack. Chronic ONS was...
No treatment is available for early-onset forms of metachromatic leukodystrophy (MLD), a lysosomal storage disease caused by autosomal recessive defect in arylsulfatase A (ARSA) gene causing severe demyelination central and peripheral nervous systems. We have developed therapy approach, based on intracerebral administration AAVrh.10-hARSA vector, coding human ARSA enzyme. previously demonstrated potency this approach MLD mice lacking expression. describe herein the preclinical efficacy,...
<h3>Objective:</h3> To confirm the efficacy and safety of deep brain stimulation (DBS) internal part globus pallidus in improving severe tardive dyskinesia (TD). <h3>Methods:</h3> Nineteen patients with pharmacoresistant TD were included. All assessed at baseline 3, 6 (main outcome measure), 12 months, long term (6–11 years) for 14 patients, after bilateral pallidal DBS, using motor scales (Extrapyramidal Symptoms Rating Scale [ESRS], Abnormal Involuntary Movement [AIMS]), cognitive scales,...
Spinal cord stimulation (SCS) is proven to effectively relieve chronic neuropathic pain. However, some implanted patients may face loss of efficacy (LoE) over time, and conversion more recent devices rescue SCS therapy. Recent systems offer novel capabilities, such as temporal modulation spatial neural targeting, can be used replace previous neurostimulators without changing existing leads. Our multicenter, observational, consecutive case series investigated real-world clinical outcomes in...
A defect of the lysosomal enzyme alpha-L-iduronidase (IDUA) interrupts degradation glycosaminoglycans in mucopolysaccharidosis type I, causing severe neurological manifestations children with Hurler's syndrome. Delivery missing through stereotactic injection adeno-associated virus vectors coding for IDUA prevents neuropathology affected mice. We examined efficacy and safety this approach enzyme-deficient dogs.Because deficient dogs raise antibodies against response to infusion, intracerebral...
Metachromatic leukodystrophy (MLD) is a lethal neurodegenerative disease caused by deficiency in the lysosomal arylsulfatase A (ARSA) enzyme leading to accumulation of sulfatides glial and neuronal cells. We previously demonstrated ARSA-deficient mice that intracerebral injection serotype 5 adeno-associated vector (AAV) encoding human ARSA corrects biochemical, neuropathological behavioral abnormalities. However, before considering potential clinical application, scaling-up issues should be...
We have previously demonstrated that delivery of a recombinant adeno-associated virus (rAAV) encoding human alpha-iduronidase (hIDUA) in the putamen and centrum semiovale was feasible beneficial dog model Hurler's syndrome. In present study, we investigated safety vector diffusion profile three rAAV serotypes (rAAV2/1, rAAV2/2, rAAV2/5), hIDUA central peripheral nervous systems nonhuman primates. Six macaques received same dose injected into right homolateral internal capsule. Neurological...
Occipital nerve stimulation (ONS) has been proposed to treat refractory chronic cluster headache (rCCH) but its efficacy only showed in small short-term series.To evaluate ONS long-term rCCH.We studied 105 patients with rCCH, treated by within a multicenter prospective registry. Efficacy was evaluated frequency, intensity of pain attacks, quality life (QoL) EuroQol 5 dimensions (EQ5D), functional (Headache Impact Test-6, Migraine Disability Assessment) and emotional (Hospital Anxiety...
Abstract The aim of this study was to evaluate the efficacy and safety bilateral pallidal (GPi) deep brain stimulation (DBS) 6 months after surgery in advanced parkinsonian patients whose dopa‐resistant axial motor signs or cognitive decline constituted contraindications for subthalamic nucleus (STN) DBS. Seventeen with a mean age 59.3 ± 7.1 years (range, 45–70), disease duration 12.5 4.3 7–20), STN DBS, underwent GPi They were evaluated before afterward, accordance Core Assessment Program...
On the basis of previous studies suggesting that vascular endothelial growth factor (VEGF) could protect motor neurons from degeneration, adeno-associated virus vectors (serotypes 1 and 9) encoding VEGF (AAV.vegf) were administered in a limb-expression (LIX1)-deficient cat-a large animal model lower neuron disease-using three different delivery routes to central nervous system. AAV.vegf injected into cortex via intracerebral administration, cisterna magna, or intravenously young adult cats....